-
公开(公告)号：KR100476636B1
公开(公告)日：2005-03-17
申请号：KR1020020054808
申请日：2002-09-11
Applicant: 한림제약(주)
IPC: C07D211/90
CPC classification number: C07D211/90
Abstract: 본 발명은 L-(+)-타르트레이트를 이용하여 광학 이성질체 R-(+)-암로디핀을 제거하고 여액에 메틸렌클로라이드를 첨가하여 순수한 S-(-)-암로디핀 에난치오머를 분리하는 대단히 간편하고 경제적인 방법에 관한 것이다.
-
公开(公告)号：KR1020030081006A
公开(公告)日：2003-10-17
申请号：KR1020030001259
申请日：2003-01-09
Applicant: 한림제약(주)
IPC: C07D211/90
Abstract: PURPOSE: Amlodipine nicotinate and a preparation process thereof are provided, which amlodipine nicotinate has improved medical efficacy, water solubility, stability, nonabsorption, etc. CONSTITUTION: An amlodipine nicotinate anhydride or hydride is provided, wherein the amlodipine nicotinate hydride has XRD pattern of figure 6. A process for preparing amlodipine nicotinate anhydride or hydride comprises reacting amlodipine with nicotinate in water-containing inert solvent, wherein 95% methanol-isopropanol or water-isopropanol(5:95) mixed solvent are used for recrystallization of the amlodipine nicotinate anhydride or hydride. The amlodipine nicotinate anhydride is prepared by drying an amlodipine nicotinate hydride under reduced pressure at 115 to 125 deg. C.
Abstract translation: 目的：提供氨氯地平烟酸酯及其制备方法，其中氨氯地平烟碱具有改善的药效，水溶性，稳定性，不吸收等。组成：提供氨氯地平烟酸酐或氢化物，其中氨氯地平烟酸氢化物具有图的XRD图 6.制备氨氯地平烟酸酐或氢化物的方法包括在含水惰性溶剂中使氨氯地平与烟酸酯反应，其中使用95％甲醇 - 异丙醇或水 - 异丙醇（5:95）混合溶剂重结晶氨氯地平烟酸酐酸酐或 氢化物。 氨氯地平烟酸酐通过在115至125℃的减压下干燥氨氯地平烟酸氢化物来制备。 C。
-
公开(公告)号：KR1020010066897A
公开(公告)日：2001-07-11
申请号：KR1020000038051
申请日：2000-07-04
Applicant: 한림제약(주)
IPC: C01B25/45
CPC classification number: C07F9/3873 , C01B25/45 , C07F9/38
Abstract: PURPOSE: A crystalline pamidronic acid disodium salt hydrate is provided, which has excellent storability and is easily processed to a preparation for oral administration. And a method for preparing thereof is also provided. CONSTITUTION: The crystalline pamidronic acid disodium salt hydrate has a water content of 17.0-20.0% and is a mixture form of pamidronic acid disodium salt trihydrate and pamidronic acid disodium salt tetrahydrate. The hydrate is represented by the following formula (1), wherein x is 3 or 4. The method comprises steps of: (i) neutralizing pamidronic acid and sodium hydroxide between pH 7.5-8.5; (ii) after filtering the produced insoluble material of the step (i), adding isopropanol to the filtrate to form a salt; (iii) after dissolving the obtained salt in water, leaving it at room temperature to crystallize it; (iv) cooling and filtering the crystallized solution of the step (iii) to obtain a crystal; and (v) drying the obtained crystal at a temperature of 75-85 deg.C under atmospheric pressure.
Abstract translation: 目的：提供结晶的帕米膦酸二钠盐水合物，其具有优异的储存性，并且易于加工成口服制剂。 还提供了其制备方法。 构成：结晶的帕米膦酸二钠盐水合物的水含量为17.0-20.0％，是一种混合形式的帕米膦酸二钠盐三水合物和帕米膦酸二钠盐四水合物。 水合物由下式（1）表示，其中x为3或4.该方法包括以下步骤：（i）在pH 7.5-8.5之间中和帕米膦酸和氢氧化钠; （ii）在过滤所产生的步骤（i）的不溶物质之后，向滤液中加入异丙醇形成盐; （iii）将得到的盐溶于水中后，将其在室温下使其结晶; （iv）冷却并过滤步骤（iii）的结晶溶液以获得晶体; 和（v）在大气压下在75-85℃的温度下干燥所得晶体。
-
公开(公告)号：KR1020000059703A
公开(公告)日：2000-10-05
申请号：KR1019990007512
申请日：1999-03-08
Applicant: 한림제약(주)
IPC: A23L2/00
Abstract: PURPOSE: A drink composition containing sea tangle extract and chitooligosaccharide is provided, wherein chitooligosaccharide is added to sea tangle extract after adjusting pH by using sodium citrate and L-arginin for preventing precipitation that occurs in case of being formed ionic bond between chitooligosaccharide and alginic acid. CONSTITUTION: The drink composition comprises 78-90 wt.% of sea tangle extract, 0.2-0.4 wt.% of chitooligosaccharide, 5-9 wt.% of saccharides, 0.7-2.5 wt.% of herbal extract, 0.5-2.5 wt.% of sodium citrate, 0.1-0.45 wt.% of L-arginin. In the drink composition, saccharides are selected from glucose, sorbitol, and oligosaccharide. The herbal extract is selected from Ganoderma lucidum extract, Rehmanniae Radix Preparata extract, and ginger extract.
Abstract translation: 目的：提供含海螯合提取物和壳低聚糖的饮料组合物，其中通过使用柠檬酸钠和L-精氨酸调节pH后，将壳寡糖加入到海螯合提取物中，以防止在壳寡糖和藻酸之间形成离子键时发生沉淀 。 构成：饮料组合物包含78-90重量％的海杂提取物，0.2-0.4重量％的壳低聚糖，5-9重量％的糖，0.7-2.5重量％的草药提取物，0.5-2.5重量％ 柠檬酸钠的百分比，0.1-0.45重量％的L-精氨酸。 在饮料组合物中，糖类选自葡萄糖，山梨糖醇和寡糖。 草药提取物选自灵芝提取物，地黄提取物和生姜提取物。
-
-
Patent Agency Ranking
-
-
-
公开(公告)号：KR101170940B1
公开(公告)日：2012-08-03
申请号：KR1020050055402
申请日：2005-06-25
Applicant: 한림제약(주) , 에이치 엘 지노믹스(주)
IPC: C07D401/12
Abstract: 본 발명은 (a) 디클로로메탄 또는 클로로포름에 판토프라졸을 용해시키는 단계; 및 (b) 수산화나트륨 수용액을 단계(a)에서 얻어진 용액에 가하여 결정화시키는 단계를 포함하는, 제1형(Form-I)의 결정성 판토프라졸 나트륨 세스퀴수화물의 제조방법을 제공한다.
본 발명의 제조방법은 별도의 반용매(anti-solvent)를 사용함이 없이 제1형(Form-I)의 결정성 판토프라졸 나트륨 세스퀴수화물을 높은 수율로 제조할 수 있으며, 또한 용매로서 사용된 디클로로메탄 또는 클로로포름을 회수하여 재사용할 수 있으므로 제조비용을 크게 낮출 수 있을 뿐 아니라, 폐용매로 인한 환경오염을 줄일 수 있다.
결정성 판토프라졸 나트륨 세스퀴수화물-
公开(公告)号：KR101151235B1
公开(公告)日：2012-06-14
申请号：KR1020110113084
申请日：2011-11-02
Applicant: 한림제약(주)
CPC classification number: A61K38/13 , A61K47/30 , A61K47/44 , Y10S514/912
Abstract: PURPOSE: A composition containing a nanoemulsion form prepared by self-emulsification using cyclosporine A together with special oil and surfactant in aqueous medium is provided to enable sterilizing and to ensure stability. CONSTITUTION: An opthalmic composition of a nanoemulsion form with 200nm or less of particles size contains 0.05 w/v% of cyclosporine A, 0.05 v/v% of propylene glycol dicaprylocaprate, 0.37 v/v% of triglyceride, and 1.15 v/v% of polyoxyl 35 hydrogenate castor oil in an aqueous medium. The composition additionally contains sodium phosphate or hydrate thereof, sodium dihydrogenphosphate or hydrate thereof, or mixture thereof.
Abstract translation: 目的：提供含有通过使用环孢菌素A与特殊油和表面活性剂在水性介质中自乳化而制备的纳米乳液形式的组合物，以便消毒并确保稳定性。 构成：具有200nm或更小颗粒尺寸的纳米乳剂形式的眼组合物含有0.05w / v％的环孢菌素A，0.05v / v％的丙二醇二辛酸钠，0.37v / v％的甘油三酸酯和1.15v / v％ 的聚氧乙烯35氢化蓖麻油在水性介质中。 该组合物还含有磷酸钠或其水合物，磷酸二氢钠或其水合物，或其混合物。
-
-
-
-
-
-
-
-
-
Search Results
86
records
(took 0.019 seconds)
